Fast Five Quiz: Precision Medicine and Genetic Testing for Colorectal Cancer

Ali Alqahtani, MD


June 17, 2022

According to 2017 guidelines on molecular biomarker testing for the evaluation of CRC from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology, tissues from metastatic or recurrent CRC are the preferred specimens for treatment-predictive biomarker testing. In their absence, primary tumor tissue is an acceptable alternative.

Formalin-fixed, paraffin-embedded tissue is an acceptable specimen for molecular biomarker mutational testing in CRC. The use of cytology specimens requires additional adequate validation, as would any changes in tissue-processing protocols.

Learn more about guidelines for biomarker testing in CRC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.